2 NRTIs

Phase 2

Merck & Co.

2 NRTIs is one of 6 therapeutic programs targeting Human Immunodeficiency Virus (HIV). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Human Immunodeficiency Virus (HIV)Recruiting

Human Immunodeficiency Virus (HIV)Phase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Human Immunodeficiency Virus (HIV)

#DrugCompanyPhaseTrials

FTC/TDF

Gilead

Phase 3

2 2

MK-8527

Merck & Co.

Phase 3

3 3

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 4

Rifadin

Sanofi

Phase 1

1 5

DOR/3TC/TDF

Merck & Co.

Phase 2

1 6

2 NRTIs

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 2Recruiting

Human Immunodeficiency Virus (HIV)

NCT04375800

Clinical

Trials by Indication[1]

Human Immunodeficiency Virus (HIV)1 trial

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT04375800·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 2 NRTIs. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 2 NRTIs. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Merck & Co.

2 NRTIs

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2034

Trials by Indication[1]

Human Immunodeficiency Virus (HIV)1 trial

References

Drug Info

Quick Facts

Related News